The KCNH2 gene provides instructions for a potassium channel that helps control the heart’s electrical reset after each beat. This gene plays an important role in keeping heart rhythm steady. If it does not work properly, the heart can take longer than usual to recharge, which may lead to long QT syndrome and raise the chance of fainting or an abnormal heart rhythm. Some variants in the KCNH2 gene are also linked to short QT syndrome, where the reset time is unusually brief.
What is a gene?
A gene is a section of DNA that carries instructions your cells use to make molecules or regulate activities in the body. Some genes provide the directions for making proteins, the parts of cells that do much of the work. Others mainly help determine when certain processes happen, where they take place, and how strongly they run. Together, genes affect how the body develops and works, and they can also influence how you respond to food, stress, or medications. To go deeper into this topic, you can find more in the LearnHub.
Overview
KCNH2Gene function
What if the gene works
The KCNH2 gene helps make a potassium channel in heart cells. This channel helps the heart reset its electrical signal between beats, supporting a steady, coordinated heartbeat.
Risk
What if the gene does not work
Changes in the KCNH2 gene can disrupt the heart’s electrical reset, usually causing long QT syndrome and less often short QT syndrome. Milder or more severe variants may affect when fainting or abnormal heart rhythms appear and how strongly.
Treatment
What does that mean for your treatment
No treatment specific to the KCNH2 gene is currently established. Care usually follows long QT syndrome guidelines, with careful avoidance of medicines that prolong the QT interval and use of standard rhythm-protective treatments when needed. The KCNH2 gene is also being studied as a marker of arrhythmia risk and future treatment response.
Conditions associated with KCNH2
Gene function
What if the gene works
Each heartbeat depends on a carefully timed flow of charged particles in and out of heart cells. The KCNH2 gene helps make a potassium channel that is active during the heart's electrical cycle. Its usual job is to help heart cells reset after each beat so the next beat can start on time.
It provides instructions for a potassium channel that sits in the outer membrane of heart cells. This channel opens and closes in response to electrical changes in the cell.
When the channel opens, potassium moves out of the cell. This outward flow helps shape the electrical signal that travels through the heart muscle.
After each heartbeat, heart cells need a brief reset before the next signal arrives. By supporting this reset phase, the channel helps control heart rhythm and keeps beat timing orderly.
What is a variant?
A genetic variant is a small alteration in the DNA sequence of a gene. These changes are common and contribute to the normal diversity seen among people, such as differences in appearance, metabolism, or the way the body responds to environmental influences. Many variants have no noticeable effect and simply represent natural genetic variation. In some cases, though, a variant can more substantially change how a gene functions and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the KCNH2 gene can alter the heart cell potassium channel by changing its shape, stability, or movement to the cell surface, showing how KCNH2 gene variants affect channel function. Some variants partly reduce potassium flow, while more severe loss of function variants can leave little or no channel activity. This range can influence whether long QT syndrome is milder or appears earlier, and rarer gain of function variants can increase channel activity and lead to short QT syndrome.
How variants are linked to conditions
Pathogenic variants in the KCNH2 gene are most strongly linked to KCNH2 gene long QT syndrome type 2, an inherited heart rhythm condition that can lead to fainting, seizures, or sudden cardiac arrest. Rare variants in the KCNH2 gene can also cause short QT syndrome. Some other KCNH2 variants may slightly influence QT interval length in the general population, but those findings describe risk trends rather than a diagnosis.
A variant is not necessarily a diagnosis
Gene variants are a usual part of human biology and are common across the general population. Most variants do not directly affect health and instead reflect normal human diversity. For many genes, carrying a variant connected with a condition indicates a possible association, not a definite diagnosis, especially when several genes and environmental factors are involved. In some situations, though, one well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For people with a disease-causing change in KCNH2, risk is driven mainly by the variant itself. Fainting or dangerous heart rhythm episodes are more likely with medicines that lengthen the QT interval, low potassium or magnesium, sudden loud noises, strong emotion, and sometimes after childbirth. Regular follow-up and avoiding known triggers can help prevent complications.
Inheritance of KCNH2 variants
The inheritance of KCNH2 gene variants is usually autosomal dominant. This means a person with a disease-causing variant in one copy of the KCNH2 gene can pass it to a child with a 50% chance in each pregnancy, regardless of the child’s sex. Some people with a KCNH2-related heart rhythm condition have a new, de novo variant that was not inherited from either parent. Once that variant is present, it can be passed on in the same autosomal dominant pattern.
What does my KCNH2 result mean for my family?
A disease-causing change in the KCNH2 gene is usually linked to a heart rhythm condition that can run in families in a dominant pattern. This means close relatives, including parents, brothers, sisters, and children, may also carry the same change, and each child has a 50% chance of inheriting it. Family members who carry it can be affected in different ways, even within the same family.
Genetic information
Genetic testing
How you find out about variants
Genetic testing for KCNH2 variants usually uses a blood or saliva sample, and the lab reads the DNA code in the KCNH2 gene to look for changes. Results may show a pathogenic variant, a variant of uncertain significance, or no relevant variant, helping clarify whether an inherited heart rhythm condition is present in the family.
When should I consider getting a genetic test?
Consider KCNH2 testing if you or close relatives have inherited long QT syndrome, a long QT on an ECG, unexplained fainting or seizures, or sudden cardiac death at a young age. A confirmed KCNH2 change can help clarify the cause and guide family testing.
A genetic result is only one part of your health story
A genetic result can provide useful insight, but how much it reveals depends on the condition and on the type of variant involved. How the body functions over time is also shaped by many other factors, including lifestyle, environment, age, and medical history. In some conditions, especially those influenced by many genes, genetic information offers context rather than certainty and is best considered alongside other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, genetic results can also help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how your body handles medicines, so the same treatment may work well for one person, feel too strong for another, or have less effect in someone else. These differences are common and can shape how a drug is absorbed, broken down, moved through the body, or how strongly the body responds to it. As a result, inherited DNA changes can influence both benefit and side effects, although other factors such as age, liver and kidney function, and other medicines also play a part.
What is Pharmacogenetics?
Pharmacogenetics examines the way genetic differences affect a person’s response to medicines. It focuses on links between genes and medications to explain why the same treatment can work differently in different people. With many drugs, genes can influence how powerfully a medicine works or how the body handles it. Understanding this can support treatment choices that are more informed and more tailored to the individual. More detailed information on this topic is available in the LearnHub.
Drugs influenced by the KCNH2 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in routine medication decisions, so any concerns about medicines or your health are best discussed with your doctor. Research on the KCNH2 gene suggests some rare changes may make certain people more likely to develop QT prolongation, an abnormal heart rhythm pattern, with some medicines, but this is not yet standard prescribing guidance.
History
The KCNH2 gene entered medical research through studies of inherited long QT syndrome, a heart rhythm condition first linked to this region in the 1990s. It was initially identified as HERG, short for “human ether-à-go-go related gene,” a name carried over from earlier work in fruit flies. Scientific classifications changed as researchers learned more about the gene. Soon after its discovery, KCNH2 became especially important in drug safety because many medicines were found to affect its activity and raise the chance of abnormal heart rhythms. That finding changed how new drugs are screened in both Europe and the United States. Today, KCNH2 is recognized as a landmark gene in both inherited arrhythmia research and modern medication safety testing.